Comparison of the effects of celiprolol and bisoprolol on central BP and measures of atherosclerosis in hypertensive patients.

Comparison of the effects of celiprolol and bisoprolol on central BP and measures of atherosclerosis in hypertensive patients. - Comparative study between celiprolol and bisoprolol (CB trial)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008913

Enrollment

100

Registered

2012-09-13

Start date

2011-02-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive patients.

Interventions

Administer celiprolol 100mg from the beginning and titrated up to 200mg for a total of 12 weeks. If the clinic BP is 140/90mmHg or more at the time of 4th week, the dose will be increased from 100 to

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.The Age>=25 years 2.Hypertensive patients 3.Patients who are not taking beta blockers 4. Secondary hypertension will be included

Exclusion criteria

Exclusion criteria: 1.Patients with malignant hypertension 2.Decompensated heart failure (NYHA III or IV) 3. Malignancy needing treatment 4.Hepatic or renal disease (serum creatinine >3.0mg/dl or under hemodialysis) 5.Those who had had severe side effects with beta blockers 6.Those with contraindication for beta blockers (bronchial asthma, bradycardia, vasospastic angina, pregnant women etc.) 7.Those with hyper- or hypoglycemic attack 8. Those with dementia from whom we cannot obtain informed consent.

Design outcomes

Primary

Measure	Time frame
1.Effects on casual blood pressure Extent of BP reduction (SBP, DBP, and mean BP) 2.Ambulatory BP Extent of BP reduction (SBP, DBP, and mean BP) 3.Pulse wave velocity (PWV), pulse wave analysis (PWA), augmentation index (AI) , central BP 4.The effects on the measures of cardiac and renal target organ damage (urinary microalbumin, hsCRP, hsTroponin T, BNP, NT-proBNP) 5.Effects on glucose and lipid 6.Effects on the measures of insulin resistance (HOMA-R) 7.Effects on autonomic nervous functions (CVRR, BRS etc)	—

Measure

Time frame

1.Effects on casual blood pressure Extent of BP reduction (SBP, DBP, and mean BP) 2.Ambulatory BP Extent of BP reduction (SBP, DBP, and mean BP) 3.Pulse wave velocity (PWV), pulse wave analysis (PWA), augmentation index (AI) , central BP 4.The effects on the measures of cardiac and renal target organ damage (urinary microalbumin, hsCRP, hsTroponin T, BNP, NT-proBNP) 5.Effects on glucose and lipid 6.Effects on the measures of insulin resistance (HOMA-R) 7.Effects on autonomic nervous functions (CVRR, BRS etc)

—

Secondary

Measure	Time frame
Adverse effects, and safety measures.	—

Countries

Japan

Contacts

Public ContactKazuo Eguchi

Jichi Medical University School of Medicine Division of Cardiovascular Medicine,Department of Medicine

ke112@jichi.ac.jp0285-58-7344

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026